Phase 2Status unknown

Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients

Efficacy and Safety of Ilaprazole for GERD: A Randomized,Double-Blind, Esomeprazole-Controlled,Phase2,Multicenter Trial in China

Sponsor
Livzon Pharmaceutical Group Inc. (Industry)
Enrollment
330 planned
Conditions
Gastroesophageal Reflux Disease
Interventions
10 mg ilaprazole; 15 mg ilaprazole; 40 mg esomeprazole
Ages
adults, older adults
Registry
NCT01107938

Full record on ClinicalTrials.gov

From the registry

This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.

Primary outcomes

  • the proportion of patients with healed esophagitis at week 8

History

  1. Primary completion

  2. Started

  3. Registered